RxDoctor Payments Data

Kurt Schwiesow, MD

Ophthalmology · Green Bay, WINPI 1215039136

Payments from drug & device makers

$2,176in general payments, 2019–2025

Across 67 payments — averaging $32.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$455
  • Glaukos Corporation$223
  • Rxsight Inc$166
  • The Cameron-ehlen Group, Inc.$81
  • Astellas Pharma US Inc$65
  • plus $93 from 4 others

What the payments were for

  • Food & beverage$2,176100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon28$1,091
AbbVie(2 entities)19$455
Glaukos Corporation10$223
Rxsight Inc2$166
The Cameron-ehlen Group, Inc.1$81
Astellas Pharma US Inc2$65
Thea Pharma Inc.2$37
Oyster Point Pharma, Inc.1$21
Novartis1$20
Aerie Pharmaceuticals, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,176 in reported general payments places this provider in the 75th percentile of 337 ophthalmology providers in Wisconsin.

See all ophthalmology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$394,074
Medicare patients
526
Services billed
2,798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost170$98,587
CombiganBrimonidine Tartrate/Timolol109$33,655
Latanoprost2,402$28,844
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol126$21,612
Prednisolone Acetate527$20,871
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,061$20,291
Brimonidine Tartrate810$19,810
Travoprost101$19,513
RestasisCyclosporine15$18,715
VyzultaLatanoprostene Bunod32$17,904
Alphagan PBrimonidine Tartrate40$17,101
Brinzolamide72$17,016
TyrvayaVarenicline Tartrate15$14,627
IlevroNepafenac36$13,534
Timolol Maleate1,278$12,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$455$168,058334 claims
Oyster Point Pharma, Inc.Tyrvaya$21$14,62715 claims
NovartisIlevro$20$13,53436 claims
AlconSimbrinza$1,091$10,36537 claims
Aerie Pharmaceuticals, Inc.Rhopressa$15$8,86818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 337 ophthalmology providers in Wisconsin.

Other ophthalmology in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →